Lifeline Biotechnologies Inc
Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States. Its technologies focus on prevention, early diagnosis, and quick recovery of various diseases. The company offers First Warning System, a non-invasive, non-compressive, and non-radiogenic device used in assisting the early discovery of breast tissue abnormalities in women. It also provides Mastascope, a … Read more
Lifeline Biotechnologies Inc (LLBO) - Total Assets
Latest total assets as of December 2009: $6.72 Million USD
Based on the latest financial reports, Lifeline Biotechnologies Inc (LLBO) holds total assets worth $6.72 Million USD as of December 2009.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lifeline Biotechnologies Inc - Total Assets Trend (2003–2018)
This chart illustrates how Lifeline Biotechnologies Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Lifeline Biotechnologies Inc - Asset Composition Analysis
Current Asset Composition (December 2018)
Lifeline Biotechnologies Inc's total assets of $6.72 Million consist of 40.3% current assets and 59.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.1% |
| Accounts Receivable | $175.06K | 39.7% |
| Inventory | $1.34K | 0.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2003–2018)
This chart illustrates how Lifeline Biotechnologies Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lifeline Biotechnologies Inc's current assets represent 40.3% of total assets in 2018, a decrease from 82.9% in 2003.
- Cash Position: Cash and equivalents constituted 0.1% of total assets in 2018, down from 23.3% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 5.0% in 2003.
- Asset Diversification: The largest asset category is accounts receivable at 39.7% of total assets.
Lifeline Biotechnologies Inc Competitors by Total Assets
Key competitors of Lifeline Biotechnologies Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Lifeline Biotechnologies Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Lifeline Biotechnologies Inc generates 0.70x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Lifeline Biotechnologies Inc generates $ 48.06 in net profit.
Lifeline Biotechnologies Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.42 | 1.58 | 1.58 |
| Quick Ratio | 8.42 | 1.33 | 1.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $531.71K | $ 40.68K | $ 40.68K |
Lifeline Biotechnologies Inc - Advanced Valuation Insights
This section examines the relationship between Lifeline Biotechnologies Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -12.4% |
| Total Assets | $440.99K |
| Market Capitalization | $0.99 USD |
Valuation Analysis
Below Book Valuation: The market values Lifeline Biotechnologies Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Lifeline Biotechnologies Inc's assets decreased by 12.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lifeline Biotechnologies Inc (2003–2018)
The table below shows the annual total assets of Lifeline Biotechnologies Inc from 2003 to 2018.
| Year | Total Assets | Change |
|---|---|---|
| 2018-12-31 | $440.99K | -12.39% |
| 2017-12-31 | $503.37K | +60.28% |
| 2016-12-31 | $314.06K | +51.63% |
| 2015-12-31 | $207.12K | -96.92% |
| 2009-12-31 | $6.72 Million | +878.08% |
| 2004-12-31 | $687.47K | -34.11% |
| 2003-12-31 | $1.04 Million | -- |